GLP-1 medications

Overview

glucagon-like peptide-1 (GLP-1) medications are a class of therapeutic agents primarily used in the management of type 2 diabetes mellitus (T2DM) and obesity. GLP-1 is an incretin hormone that plays a crucial role in glucose metabolism by enhancing insulin secretion in a glucose-dependent manner, inhibiting glucagon release, and promoting satiety. These medications mimic the action of endogenous GLP-1, leading to improved glycemic control and weight loss. Their biological significance extends beyond glucose regulation, as they are also implicated in β-cell survival and regeneration, making them a focal point in diabetes research.

Focus of Latest Publications

Recent investigations reveal a rapid evolution in GLP-1-based therapeutics beyond single-agonist approaches. The clinical success of GLP-1 receptor agonists has catalyzed a paradigm shift toward multi-agonist therapies targeting interconnected metabolic peptide signaling. Dual agonists targeting glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptors, exemplified by tirzepatide, have emerged as efficacious alternatives for obesity and post-bariatric surgical weight regain. Triple agonists engaging GLP-1, GIP, and glucagon receptors (such as retatrutide) are under investigation for both metabolic and renal protection in chronic kidney disease. Notably, alternative pathways lacking GLP-1 activity—including GIP receptor and glucagon receptor co-agonism—have demonstrated obesity reversal in animal models, suggesting therapeutic benefits may extend beyond classical GLP-1 signaling. Gene therapy approaches using lentiviral vectors encoding native GLP-1 have shown developmental stage-dependent effects on pancreatic β-cell regeneration, effectively promoting neogenesis in neonatal models and partially restoring regenerative capacity in adult diabetic animals.

The therapeutic scope of GLP-1 medications has broadened to encompass metabolic liver disease, with semaglutide now approved for metabolic dysfunction-associated steatohepatitis (MASH) with moderate-to-severe fibrosis. Preclinical studies in translational mouse models confirm semaglutide's efficacy in improving hepatic steatosis, inflammation, and fibrosis histology—findings that closely parallel pivotal clinical trial outcomes. GLP-1 agonists are increasingly being evaluated in liver transplant recipients and post-bariatric surgery populations, where enhanced post-meal GLP-1 and peptide YY responses correlate with improved glucose homeostasis, reduced hunger, and enhanced cognitive control toward food cues. Mechanistic studies reveal that GLP-1 receptor agonists augment endogenous GLP-1 secretion in patients receiving concurrent basal Insulin Therapy, suggesting synergistic hormonal interactions when combined with other metabolic therapies.

Pharmacological innovations aim to optimize GLP-1 bioavailability and duration. Proteolysis-targeting chimera (PROTAC) technology has been leveraged to develop heterobifunctional degraders of dipeptidyl peptidase-4 (DPP-4), the enzyme that rapidly cleaves GLP-1. Single-dose administration of DPP-4 degraders achieved sustained glycemic control exceeding five times the duration of conventional DPP-4 inhibitors, with enhanced endogenous GLP-1 elevation and glucose tolerance. Computational systems dynamics modeling of semaglutide has generated mechanistic hypotheses regarding its long-term effects on body weight, energy intake, insulin sensitivity, and neural activity in appetite-regulating brain regions. Emerging clinical considerations include gastrointestinal motility adverse events and aesthetic concerns related to rapid weight loss—including facial fat reduction and skin laxity—alongside documented gaps in clinical support for telehealth-delivered GLP-1 care that warrant further investigation.

Key Publications

• NEWJun The evolving therapeutic landscape of gut-pancreatic peptide signalling in metabolic disorders: from mono- to multi-agonist therapies. (Bioscience reports, 2026, PMID 42307179): "The emergence of glucagon-like peptide-1 (GLP-1) receptor agonists represents a watershed moment, fundamentally reshaping the therapeutic landscape for both T2D and obesity due to multifaceted metabolic benefits."
• NEWJun Lentiviral GLP-1 gene therapy elicits developmental stage-dependent β-cell regeneration in diabetic rats. (Journal of molecular medicine (Berlin, Germany), 2026, PMID 42277427): "Glucagon-like peptide-1 (GLP-1) promotes β-cell survival, proliferation, and differentiation; however, its developmental stage-specific effects on β-cell regeneration are not fully understood."
• NEWJun Impact of Glucagon-Like Peptide-1 Agonist Use on Weight Trajectory and Clinical Outcomes Following Liver Transplantation. (Transplantation proceedings, 2026, PMID 42259739): "Glucagon-Like Peptide-1 (GLP-1) analogues are increasingly being used to manage diabetes and obesity."
• NEWJun PROTAC-Mediated DPP-4 Degradation: A New Solution for Type 2 Diabetes. (Journal of medicinal chemistry, 2026, PMID 42260272): "Dipeptidyl peptidase-4 (DPP-4) is an important aggravating factor in the progression and exacerbation of type 2 diabetes mellitus (T2DM), a condition characterized by diminished insulin responsiveness because it rapidly degrades glucagon-like peptide-1 (GLP-1) and other peptide with similar physiological function."
• Jun Glucagon-Like Peptide-1 Based Therapies and the Risk of Severe Gastrointestinal Motility Adverse Events: A Cohort Study. (Diabetes, obesity & metabolism, 2026, PMID 42244136): "Evidence showing the association between glucagon-like 1 (GLP-1) based therapies and severe gastrointestinal motility events is limited and possible treatment effect heterogeneity by demographic and clinical characteristics is unknown."
• Jun Tirzepatide for Recurrent Weight Gain after Bariatric Procedures: Real-World Evidence of Efficacy and Safety. (Obesity surgery, 2026, PMID 42247124): "Tirzepatide, a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, has shown promising results in obesity treatment, but data regarding its use in post BS or EBT recurrent weight gain are limited."
• Jun Associations of PYY, GLP-1 and LEAP2 with changes in feeding-related cognition, body weight and glucose homeostasis after bariatric surgery in non-diabetic women. (Journal of neuroendocrinology, 2026, PMID 42210737): "Plasma glucose, insulin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY), ghrelin, and liver-expressed antimicrobial peptide 2 (LEAP2) were measured before and after a breakfast in all visits."
• Jun Aesthetic Concerns and Nonsurgical Treatment Trends in Patients With GLP-1 Agonist-Associated Weight Loss. (Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2026, PMID 42210883): "Weight loss associated with glucagon-like peptide-1 (GLP-1) agonists is frequently accompanied by reduced facial fat, sagging skin, and stubborn pockets of body fat."
• May After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care. (Journal of medical Internet research, 2026, PMID 42206886): "GLP-1 medications offer promise for obesity management and are increasingly accessible via digital platforms."
• Jun GIPR:GCGR co-agonism restores normal weight in obese rodents. (Molecular metabolism, 2026, PMID 41997446): "Functional co- and tri-agonists at the receptors for GLP-1, GIP and glucagon effectively decrease body weight and hyperglycemia but are associated with adverse gastrointestinal effects related to GLP-1R agonism."